PR Newswire Clinical TrialsOriginal article
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease
PartnershipBHV-1300Positive
AI Analysis
Summary
Biohaven entered an exclusive licensing agreement with Ono Pharma to develop and commercialize its MoDE pan IgG degraders platform, including lead candidate BHV-1300 in Phase 3 for Graves' Disease, across Japan and select Asian regions. Biohaven will receive up to $100 million in near-term payments from the deal.
Clinical Trial Data
Phase
Phase 3
Outcome Details
Exclusive licensing agreement for extracellular IgG degraders in Japan and select Asian regions
Importance:7/10
Sentiment:
0.70
licensingpartnershipPhase 3Graves' DiseaseIgG degradersinternational expansionJapanAsia
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on October 8, 2026 8:00 AM